12:00 AM
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nivolumab: Preliminary Phase II data

Preliminary data from the Japanese Phase II ONO-4538-02 trial in 35 previously treated advanced melanoma patients showed that 2 mg/kg IV nivolumab every 3 weeks led to an ORR of 23%. Median PFS was 172 days and median OS had not yet been reached. No treatment-related...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >